Astellas VP-Business Development Masaki Doi: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese pharma exec discusses Astellas’ global licensing strategy, the FibroGen deal, and the changing paradigm of Japanese deal flow.
You may also be interested in...
Astellas Sees Further FDA Action On Prograf MR In Early 2008
Astellas responded in July to an "approvable" letter received in January for use of the immunosuppressant Prograf MR (tacrolimus) in liver transplantation, the Japanese pharma revealed during its first quarter 2007 earnings call August 1
Astellas Sees Further FDA Action On Prograf MR In Early 2008
Firm and partner FibroGen also plan response to FDA’s clinical hold on their novel EPO candidates by year end.
Astellas Sees Further FDA Action On Prograf MR In Early 2008
Firm and partner FibroGen also plan response to FDA’s clinical hold on their novel EPO candidates by year end.